Barclays PLC Alnylam Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 105,185 shares of ALNY stock, worth $25.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

105,185

Previous 105,185 -0.0%

Holding current value

$25.8 Million

Previous $28.9 Million -0.0%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$233.81 - $287.01 $6.1 Million - $7.49 Million	-26,080 Reduced 19.87%	105,185 $28.9 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $8.99 Million - $15.5 Million	-62,707 Reduced 32.33%	131,265 $31.9 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $7.61 Million - $10.3 Million	51,972 Added 36.6%	193,972 $29 Million
Q4 2023 Feb 15, 2024	SELL	$151.41 - $196.57 $3.06 Million - $3.97 Million	-20,195 Reduced 12.45%	142,000 $27.2 Million
Q3 2023 Nov 07, 2023	SELL	$170.77 - $211.65 $8.19 Million - $10.1 Million	-47,950 Reduced 22.82%	162,195 $28.7 Million
Q2 2023 Aug 03, 2023	BUY	$185.01 - $212.05 $12.7 Million - $14.5 Million	68,550 Added 48.41%	210,145 $39.9 Million
Q1 2023 May 04, 2023	SELL	$182.66 - $235.53 $3.75 Million - $4.84 Million	-20,539 Reduced 12.67%	141,595 $28.4 Million
Q4 2022 Feb 13, 2023	BUY	$185.53 - $241.31 $3.86 Million - $5.01 Million	20,780 Added 14.7%	162,134 $38.5 Million
Q3 2022 Nov 03, 2022	BUY	$138.54 - $232.0 $2.11 Million - $3.53 Million	15,233 Added 12.08%	141,354 $28.3 Million
Q2 2022 Aug 12, 2022	BUY	$120.42 - $169.29 $5.6 Million - $7.88 Million	46,523 Added 58.45%	126,121 $18.4 Million
Q1 2022 May 16, 2022	SELL	$127.18 - $173.91 $301,035 - $411,644	-2,367 Reduced 2.89%	79,598 $13 Million
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $2.47 Million - $3.25 Million	-15,510 Reduced 15.91%	81,965 $13.9 Million
Q3 2021 Nov 09, 2021	SELL	$169.75 - $207.73 $942,282 - $1.15 Million	-5,551 Reduced 5.39%	97,475 $18.4 Million
Q2 2021 Aug 13, 2021	BUY	$128.63 - $176.89 $3.24 Million - $4.45 Million	25,161 Added 32.31%	103,026 $17.5 Million
Q1 2021 May 13, 2021	BUY	$126.83 - $175.69 $1.89 Million - $2.62 Million	14,890 Added 23.64%	77,865 $11 Million
Q4 2020 Feb 11, 2021	SELL	$122.97 - $147.0 $3.88 Million - $4.63 Million	-31,520 Reduced 33.36%	62,975 $8.19 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $2.63 Million - $3.59 Million	-21,693 Reduced 18.67%	94,495 $13.8 Million
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $1.4 Million - $2.11 Million	13,473 Added 13.12%	116,188 $17.2 Million
Q1 2020 May 13, 2020	BUY	$93.12 - $133.99 $3.87 Million - $5.57 Million	41,557 Added 67.95%	102,715 $11.2 Million
Q4 2019 Feb 10, 2020	SELL	$74.51 - $124.23 $2.96 Million - $4.94 Million	-39,729 Reduced 39.38%	61,158 $7.04 Million
Q3 2019 Nov 14, 2019	BUY	$70.9 - $87.82 $2.48 Million - $3.07 Million	34,994 Added 53.11%	100,887 $8.11 Million
Q2 2019 Aug 14, 2019	BUY	$65.86 - $92.79 $1.04 Million - $1.46 Million	15,770 Added 31.46%	65,893 $4.78 Million
Q1 2019 May 15, 2019	SELL	$72.76 - $93.45 $1.71 Million - $2.19 Million	-23,443 Reduced 31.87%	50,123 $4.68 Million
Q4 2018 Feb 14, 2019	BUY	$62.67 - $88.33 $243,911 - $343,780	3,892 Added 5.59%	73,566 $5.36 Million
Q3 2018 Nov 14, 2018	BUY	$87.52 - $122.67 $1.71 Million - $2.4 Million	19,562 Added 39.04%	69,674 $6.1 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $2.92 Million - $3.57 Million	33,094 Added 194.46%	50,112 $4.94 Million
Q1 2018 May 15, 2018	SELL	$115.92 - $148.54 $7.94 Million - $10.2 Million	-68,526 Reduced 80.11%	17,018 $2.03 Million
Q4 2017 Feb 14, 2018	BUY	$114.49 - $139.98 $8.48 Million - $10.4 Million	74,097 Added 647.3%	85,544 $10.9 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $830,250 - $1.35 Million	11,447	11,447 $1.34 Million

Others Institutions Holding ALNY

# of Institutions

642

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account